Clinical trial to study the effects of Stemedica’s proprietary mesenchymal stem cells in patients with traumatic brain injury SAN DIEGO, California – May 18, 2016. Stemedica received an FDA investigational new drug (IND)…
ABSTRACT Developing effective therapies for heart failure (HF) is challenging. Despite several clear successes in the development and delivery of pharmacotherapies for ambulatory patients with HF and reduced ejection fraction (HFrEF), efforts to modulate adverse…
Abstract Compared with heart failure (HF) care 20 to 30 years ago, there has been tremendous advancement in therapy for ambulatory HF with reduced ejection fraction with the use of agents that block maladaptive neurohormonal pathways. However, during the past decade,…
San Diego, California, January 27, 2016: Stemedica announced completion of enrollment into “A Phase I/IIa, Multi-Center, Open-Label Study to Assess the Safety, Tolerability, and Preliminary Efficacy of a Single Intravenous Dose of Allogeneic…
Stemedica expands manufacturing capacity for Phase III and commercial stem cell products San Diego, California and Epalinges, Switzerland – November 10, 2015 – Stemedica a leading manufacturer of adult, allogeneic stem cells and preserved stem…
Abstract Over the past 1.5 decades, numerous stem cell trials have been performed in patients with cardiovascular disease. Although encouraging outcome signals have been reported, these have been small, leading to uncertainty as to whether they will translate into…
Abstract Aims: This article describes an ongoing study investigating the safety and efficacy of ischemia-tolerant mesenchymal stem cell (MSC) therapy in patients with nonischemic heart failure and dysfunctional viable myocardium without scarring. This study will…
Possible Modulating Effects of Paracrine Activities of Stem Cells Abstract Over the past 1.5 decades, numerous stem cell trials have been performed in patients with cardiovascular disease. Although encouraging outcome signals have been reported, these have been small,…
Stemedica a leading manufacturer of adult, allogeneic stem cells and stem cell factors, received United States Patent No. 9080184 entitled “Transgenic Therapeutic Stem Cells and Methods for Their Use and Manufacture.” The patent issued on July…
Stemedica a leading manufacturer of adult, allogeneic stem cells and stem cell factors, received a new patent from the U.S. Patent & Trademark Office, US8709081 entitled “Cellular Scaffold.” This patent, coupled with the US8105380 patent…
Planned to Launch in the Fourth Quarter 2015 in the United States as the First Alzheimer’s Clinical Trial Using Intravenous Administration of Ischemia-Tolerant Mesenchymal Stem Cells (itMSCs) SAN DIEGO and Epalinges, Switzerland — June 9, 2015 — Stemedica ….
Commercial-scale Preservation of Therapeutically-active Stem Cell-derived Products For Worldwide Marketplace Opportunities SAN DIEGO—March 24, 2015—Stemedica announced today that Universal Stabilization Technologies (UST) has…
